Your browser doesn't support javascript.
loading
Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile.
Nussbaumer, Gunther; Benesch, Martin; Grabovska, Yura; Mackay, Alan; Castel, David; Grill, Jacques; Alonso, Marta M; Antonelli, Manila; Bailey, Simon; Baugh, Joshua N; Biassoni, Veronica; Blattner-Johnson, Mirjam; Broniscer, Alberto; Carai, Andrea; Colafati, Giovanna Stefania; Colditz, Niclas; Corbacioglu, Selim; Crampsie, Shauna; Entz-Werle, Natacha; Eyrich, Matthias; Friker, Lea L; Frühwald, Michael C; Garrè, Maria Luisa; Gerber, Nicolas U; Giangaspero, Felice; Gil-da-Costa, Maria J; Graf, Norbert; Hargrave, Darren; Hauser, Peter; Herrlinger, Ulrich; Hoffmann, Marion; Hulleman, Esther; Izquierdo, Elisa; Jacobs, Sandra; Karremann, Michael; Kattamis, Antonis; Kebudi, Rejin; Kortmann, Rolf-Dieter; Kwiecien, Robert; Massimino, Maura; Mastronuzzi, Angela; Miele, Evelina; Morana, Giovanni; Noack, Claudia M; Pentikainen, Virve; Perwein, Thomas; Pfister, Stefan M; Pietsch, Torsten; Roka, Kleoniki; Rossi, Sabrina.
Afiliação
  • Nussbaumer G; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
  • Benesch M; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
  • Grabovska Y; Division of Molecular Pathology, Institute of Cancer Research, London, UK.
  • Mackay A; Division of Molecular Pathology, Institute of Cancer Research, London, UK.
  • Castel D; U981, Molecular Predictors and New Targets in Oncology, Team Genomics and Oncogenesis of Pediatric Brain Tumors, INSERM, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Grill J; Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Alonso MM; U981, Molecular Predictors and New Targets in Oncology, Team Genomics and Oncogenesis of Pediatric Brain Tumors, INSERM, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Antonelli M; Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Bailey S; Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
  • Baugh JN; Solid Tumor Program, Center for the Applied Medical Research, Pamplona, Navarra, Spain.
  • Biassoni V; Health Research Institute of Navarra (IdiSNA), Pamplona, Navarra, Spain.
  • Blattner-Johnson M; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University, Rome, Italy.
  • Broniscer A; Department of Paediatric Oncology, Sir James Spence Institute of Child Health, Royal Victoria Infirmary Queen Victoria Road, Newcastle upon Tyne, UK.
  • Carai A; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Colafati GS; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Colditz N; Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Corbacioglu S; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
  • Crampsie S; Division of Hematology-Oncology, Children's Hospital of Pittsburgh, Pittsburgh, PA, U.S.A.
  • Entz-Werle N; Neurosurgery Unit, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
  • Eyrich M; Oncological Neuroradiology and Advanced Diagnostics Unit, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
  • Friker LL; Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Frühwald MC; Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.
  • Garrè ML; Division of Molecular Pathology, Institute of Cancer Research, London, UK.
  • Gerber NU; UMR CNRS 7021-Laboratory of Bioimagery and Pathologies Team tumor signaling and therapeutic targets, University of Strasbourg, Illkirch, France.
  • Giangaspero F; Pediatric Onco-Hematology Department-Pediatrics III, University Hospital of Strasbourg, Strasbourg, France.
  • Gil-da-Costa MJ; Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.
  • Graf N; Institute of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Bonn, Germany.
  • Hargrave D; Pediatric and Adolescent Medicine, Swabian Children's Cancer Center, University Medical Center Augsburg, Augsburg, Germany.
  • Hauser P; Neuro-Oncology Unit, IRCSS Istituto Giannina Gaslini, Genoa, Italy.
  • Herrlinger U; Department of Oncology and Children's Research Centre, University Children's Hospital, Zurich, Switzerland.
  • Hoffmann M; Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University, Rome, Italy.
  • Hulleman E; Pediatric Oncology Department, University Hospital São João, Porto, Portugal.
  • Izquierdo E; Department of Pediatric Oncology and Hematology, Saarland University, Homburg, Germany.
  • Jacobs S; Pediatric Oncology, Great Ormond Street Hospital for Children, London, UK.
  • Karremann M; Second Department of Pediatrics, Semmelweis University, Budapest, Hungary.
  • Kattamis A; Division of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn, Bonn, Germany.
  • Kebudi R; Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Kortmann RD; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Kwiecien R; Division of Molecular Pathology, Institute of Cancer Research, London, UK.
  • Massimino M; Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Belgium.
  • Mastronuzzi A; Pediatric Oncology, Department of Oncology, KU Leuven, Belgium.
  • Miele E; Department of Pediatric and Adolescent Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Morana G; Division of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece.
  • Noack CM; Division of Pediatric Hematology-Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
  • Pentikainen V; Department of Radiation Oncology, University of Leipzig, Leipzig, Germany.
  • Perwein T; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
  • Pfister SM; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Pietsch T; Department of Onco-Hematology, Gene and Cell Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
  • Roka K; Department of Onco-Hematology, Gene and Cell Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
  • Rossi S; Department of Neurosciences, University of Turin, Turin, Italy.
Neuro Oncol ; 26(9): 1723-1737, 2024 Sep 05.
Article em En | MEDLINE | ID: mdl-38717379
ABSTRACT

BACKGROUND:

The term gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features could not be established.

METHODS:

We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization.

RESULTS:

Median overall survival (OS) was 15.5 months (interquartile range, 10.9-27.7) with a 2-year survival rate of 28%. Histopathological grading correlated significantly with median OS CNS WHO grade II 47.8 months (25.2-55.7); grade III 15.9 months (11.4-26.3); grade IV 10.4 months (8.8-14.4). By DNA methylation profiling (n = 49), most tumors were classified as pediatric-type diffuse high-grade glioma (pedHGG), H3-/IDH-wild-type (n = 31/49, 63.3%) with enriched subclasses pedHGG_RTK2 (n = 19), pedHGG_A/B (n = 6), and pedHGG_MYCN (n = 5), but only one pedHGG_RTK1 case. Within the pedHGG, H3-/IDH-wild-type subgroup, recurrent alterations in EGFR (n = 10) and BCOR (n = 9) were identified. Additionally, we observed structural aberrations in chromosome 6 in 16/49 tumors (32.7%) across tumor types. In the pedHGG, H3-/IDH-wild-type subgroup TP53 alterations had a significant negative effect on OS.

CONCLUSIONS:

Contrary to previous studies, our representative pediatric GC study provides evidence that GC has a strong predilection to arise on the background of specific molecular features (especially pedHGG_RTK2, pedHGG_A/B, EGFR and BCOR mutations, chromosome 6 rearrangements).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias Neuroepiteliomatosas / Glioma Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Neuro Oncol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias Neuroepiteliomatosas / Glioma Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Neuro Oncol Ano de publicação: 2024 Tipo de documento: Article